Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Lymphoblastic Leukaemia ◽

Adult Patients ◽

Adverse Event Profile ◽

Open Label ◽

Inotuzumab Ozogamicin ◽

Phase 3 ◽

Hepatic Adverse Event

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00363-0 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1677-1690 ◽

Cited By ~ 101

Author(s):

Andrew E Place ◽

Kristen E Stevenson ◽

Lynda M Vrooman ◽

Marian H Harris ◽

Sarah K Hunt ◽

...

Keyword(s):

Escherichia Coli ◽

Lymphoblastic Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Faculty Opinions recommendation of Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725924636.793524748 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

Escherichia Coli ◽

Lymphoblastic Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Faculty Opinions recommendation of Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725924636.793530156 ◽

2017 ◽

Author(s):

Kjeld Schmiegelow

Keyword(s):

Escherichia Coli ◽

Lymphoblastic Leukaemia ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00328-4 ◽

2021 ◽

Author(s):

Wenyu Yang ◽

Jiaoyang Cai ◽

Shuhong Shen ◽

Ju Gao ◽

Jie Yu ◽

...

Keyword(s):

Childhood Acute Lymphoblastic Leukaemia

Lymphoblastic Leukaemia ◽

Pulse Therapy ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.7823960.8163058 ◽

2011 ◽

Author(s):

Jan Starý ◽

Jana Volejnikova

Keyword(s):

Lymphoblastic Leukaemia ◽

Randomised Trial ◽

Open Label ◽

First Relapse

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71170-2 ◽

2015 ◽

Vol 16 (1) ◽

pp. 57-66 ◽

Cited By ~ 638

Author(s):

Max S Topp ◽

Nicola Gökbuget ◽

Anthony S Stein ◽

Gerhard Zugmaier ◽

Susan O'Brien ◽

...

Keyword(s):

Lymphoblastic Leukaemia ◽

Adult Patients ◽

Phase 2 ◽

Phase 2 Study

DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30154-7 ◽

2017 ◽

Vol 18 (4) ◽

pp. 515-524 ◽

Cited By ~ 35

Author(s):

Stine Nygaard Nielsen ◽

Kathrine Grell ◽

Jacob Nersting ◽

Jonas Abrahamsson ◽

Bendik Lund ◽

...

Keyword(s):

Maintenance Therapy ◽

Lymphoblastic Leukaemia ◽

Relapse Free Survival ◽

Phase 3 ◽

Free Survival ◽

Thioguanine Nucleotide

Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin Versus Investigators Choice (IC) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)

Value in Health ◽

10.1016/j.jval.2017.08.288 ◽

2017 ◽

Vol 20 (9) ◽

pp. A449

Author(s):

R Batteson ◽

S Critchlow ◽

A Barnes ◽

D Glah ◽

A Smith ◽

...

Keyword(s):

B Cell ◽

Lymphoblastic Leukaemia ◽

Quality Adjusted Life Years ◽

Inotuzumab Ozogamicin ◽

Life Years ◽

Quality Adjusted Life

Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia

British Journal of Haematology ◽

10.1111/j.1365-2141.2005.05544.x ◽

2005 ◽

Vol 130 (2) ◽

pp. 166-173 ◽

Cited By ~ 41

Author(s):

James Nachman

Keyword(s):

Young Adult ◽

Lymphoblastic Leukaemia ◽

Clinical Characteristics ◽

Adult Patients

Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: A retrospective study

European Journal Of Haematology ◽

10.1111/j.1600-0609.1992.tb00032.x ◽

2009 ◽

Vol 49 (2) ◽

pp. 63-66 ◽

Cited By ~ 80

Author(s):

Luigi Gugliotta ◽

Maria-Gabriella Mazzucconi ◽

Giuseppe Leone ◽

Monica Mattioli-Belmonte ◽

Daniela Defazio ◽

...

Keyword(s):

Retrospective Study ◽

Induction Therapy ◽

Lymphoblastic Leukaemia ◽

Adult Patients ◽

Thrombotic Complications